세계의 유전성 질환 파트너링(2014-2021년) : 거래 동향, 기업, 재무 정보
Global Genetic Disorders Partnering 2014-2021: Deal trends, players and financials
상품코드 : 939910
리서치사 : Current Partnering, a division of Wildwood Ventures Limited
발행일 : 2021년 04월
페이지 정보 : 영문 400+ Pages
US $ 3,495 ₩ 3,959,000
PDF (Single User License)
US $ 5,245 ₩ 5,941,000
PDF (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 11,888,000
PDF (Single Site License - 6+ Users)
US $ 17,495 ₩ 19,818,000
PDF (Global License)


한글목차

유전성 질환의 치료제 개발에 관한 최근(2014-2021년) 제휴 거래의 동향에 대해 분석했으며, 전체적인 거래 성립 건수의 추이, 재무면(지불 조건)에서의 동향, 주요 기업에 의한 거래 성립 동향, 계약 조건의 동향, 적응증별(치료 표적별) 동향 등을 조사하고, 최근 주요 제휴 거래 상세 정보를 정리하여 전해드립니다.

목차

개요

제1장 서론

제2장 유전성 질환 관련 거래 성립의 동향

제3장 유전성 질환 파트너링 : 재무면의 조건

제4장 유전성 질환 관련 대표적인 거래

제5장 유전성 질환의 계약 문서 디렉토리

제6장 유전성 질환 관련 거래 성립 : 치료 표적별

부록

KSA 20.06.17
영문 목차

영문목차

Global Genetic Disorders Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies

Global Genetic Disorders Partnering 2014 to 2021 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Genetic Disorders partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Genetic Disorders partnering agreement structure

Genetic Disorders partnering contract documents

Top Genetic Disorders deals by value

Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2014. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2014 to 2021 includes:

In Global Genetic Disorders Partnering 2014 to 2021, available deals and contracts are listed by:

The Global Genetic Disorders Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 590 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

Benefits

Global Genetic Disorders Partnering 2014 to 2021 provides the reader with the following key benefits:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking

Chapter 3 -Financial deal terms for Genetic Disorders partnering

Chapter 4 - Leading Genetic Disorders deals and dealmakers

Chapter 5 - Genetic Disorders contract document directory

Chapter 6 - Genetic Disorders dealmaking by therapeutic target

Appendices

TABLE OF FIGURES

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기